Heart disease is the leading cause of death and illness in the Western World, and is responsible for over 600,000 deaths per year in the US alone. SCT is dedicated to revolutionizing medical treatments for the heart through the use of pluripotent stem cells. Our “disease in a dish” and “clinical trial in a dish” platforms are currently in use for development of cardiovascular drugs as well as safety tests of non-cardiac drugs for cardiotoxicity. SCT was formally launched in 2013 by professors Bobby Robbins and Joseph Wu, graduate student Andrew Lee, and undergraduate student researcher Divya Nag.


Robert Robbins, MD

Robert Robbins, MD is the President and CEO of the Texas Medical Center in Houston, Texas. He was previously the Chair of Cardiothoracic Surgery and the Director of the Cardiovascular Institute at the Stanford University School of Medicine, where he served as faculty for 20 years. Dr. Robbins is a pioneer in the use of stem cells for treatment of heart failure as well as genetic determinants of cardiovascular disorders. He has authored over 300 articles and 30 book chapters on these topics.

Joseph Wu, MD, PhD

Joseph Wu, MD, PhD is the Director of the Stanford Cardiovascular Institute, a Professor of Medicine/Cardiology & Radiology at Stanford University School of Medicine, and a White House recognized physician-scientist. As a cardiovascular medicine specialist, he regularly sees patients in a congenital heart disease clinic at Stanford Hospital. He has published over 200 peer-reviewed articles in the cardiovascular research field.

Andrew Lee

Andrew Lee is an MD/PhD student at Stanford University in the Department of Chemical Systems Biology. As a graduate student in the laboratories of Dr. Wu and Dr. Robbins, Andrew has published over 35 peer reviewed research manuscripts on the use of stem cells for treatment of heart disease and drug screening. Andrew is a co-founder of the Medical Vertical of the Stanford Student Startup Accelerator StartX.